Loading
A phase 2 trial of Durvalumab, Bevacizumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE is a phase 2 interventional study registered as NCT06040099 by AstraZeneca, with 58 participants enrolled, started 2024-02-13 and due to reach its primary completion in 2026-07-01. Interventions recorded: Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE). Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.
Shares Durvalumab, Bevacizumab, Anti-angiogenic therapy, AstraZeneca.
Shares Durvalumab, Bevacizumab, Anti-angiogenic therapy, AstraZeneca.
Shares Durvalumab, Anti-angiogenic therapy, AstraZeneca, Hepatocellular carcinoma.
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Bevacizumab, Anti-angiogenic therapy, AstraZeneca.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Durvalumab, Bevacizumab, AstraZeneca, Immune checkpoint inhibitors.